СОВРЕМЕННЫЕ АСПЕКТЫ ЦИТОЛОГИЧЕСКОГО СКРИНИНГА РАКА ШЕЙКИ МАТКИ: ОБЗОР
https://doi.org/10.17650/1994-4098-2009-0-3-4-78-83
Аннотация
Ежегодно в мире регистрируется более 500 000 случаев заболевания раком шейки матки среди женщин. При этом почти половина боль- ных умирает в течение первого года в связи с поздней диагностикой заболевания. В связи с этим проблема ранней диагностики рака на се- годняшний день встает особенно остро.
Список литературы
1. Ferlay J., Bray F., Pisani P. et al. Globocan 2002: Cancer incidence, mor- tality and prevalence. Worldwide. IARC Cancer Base No5. Version 2.0. Lyon, France: IARC Press, 2004.
2. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year. The global picture. Eur J Cancer 2000;37(8):4—66.
3. Статистика злокачественных новообразований в России и странах СНГ в 2006 г. Под ред. М.И. Давыдова, Е.М. Аксель. Вестн РОНЦ РАМН им. Н.Н. Блохина 2008;2(19):прил 1.
4. Злокачественные новообразования в России в 2002 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена, 2004.
5. Ferlay J., Bray F., Pisani P. et al. Globocan 2000: Cancer incidence, mor- tality and prevalence worldwide, IARC Cancer Base No 5, Version 1.0. Lyon, France: IARC press, 2001.
6. UK National office of Statistics: http//www.statistics.gov uk / Stat base/is data set. asp ? vink =9096-last accessed on 01.05.06
7. US Cancer Statistics Working Group. United States Cancer Statistics: 2004 Mortality. Atlanta (GA): department of Health and Human Services, Centers Control and Prevention, and National Cancer Institute, 2007.
8. Wang S.S., Sherman M.E., Hildesheim A. et al. Cervical adenocarci- noma and squamous cell carcinoma inci- dence trends among white women and black women in the United States for 1976—2000. Cancer 2004;100(5):1035—44.
9. Sherman N.E., Wang S.S., Carreon J. et al. Mortality trends for cervical squa- mous and adenocarcinoma in the United States. Relation to incidence and sur- vival. Cancer 2005;103(6):1258—64.
10. Kyndi M., Frederiksen K., Kruger K. Cervical cancer incidence in Denmark over six decades (1943—2002). Acta Obstet Gynecol Scand 2006;85(1):106—11.
11. National Cancer Institute United States Cancer Statistic: 2002 Incidence and Mortality.
12. Munoz N. Human papillomavirus and cancer: the epidemiological evi- dence. J Clin Virol 2000:19:1—5.
13. Walboomers J.M.M., Jacobs M.V., Manos M.M. et al. Human papilo- mavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12—9.
14. Kapeu A.S., Luostarinen T., Jellum E. et al. Is smoking an independent risk fac- tor for invasive cervical cancer? A Nested Case-Control Study within Nordic Biobanks.
15. Castlehttp P.E.://www.imaginis. Com/cervical-cancer/news/ news2.09.03.asp
16. Roteli-Martins C.M., Panetta K., Alves V.A. et al. Cigarette smoking and high-risk HPV DNA as predisposing fac- tors for high-grade cervical intraepithelial neoplasia (CIN) in young Brazilian women. Act Obstet Gynecol Scandinav 1998;77(6):678.
17. Coker A.L., Bond S.M., Williams A. et al. Active and passive smoking, high- risk human papillomaviruses and cervical neoplasia. Cancer Detect Prev 2002;26(2):121—8.
18. Wieland U., Pfister H. Papillomavirus in human pathology. Epidemiology, pathogenesis and onco- genic role. In Human Papilloma Virus: A clinical atlas. Gross , Barrasso eds. Ulstein Mosby, 1997. p. 1—18.
19. Monsonego J. Prevention of cervical cancer (II): Prophylactic HPV vaccina- tion, current knowledge, practical proce- dures and new issues. Press Med 2007;36(7—8):1150—1.
20. WHO. Press Release, 1996; 47.
21. Baay M.F., Verhoeven V., Avonts D. et al. Risk factors for cervical cancer development: what do women think? Sex Health 2004;1:145—9.
22. Castle P. Cervical cancer: epidemiol- ogy and prevention. NCI summer cur- riculum in cancer prevention. July 2 through 27, 2007 Module 4-Screening and Early Detection.
23. Аксель Е.М., Двойрин В.В., Трапезников Н.Н. Заболеваемость и смертность от злокачественных новообразований населения России и стран СНГ в 1992 г. М., 1994.
24. Pettersson F., Naslund I., Walker B. Evaluation of the effect of papanicolaou screening in Sweden: record linkage between a central screening registry and the national cancer registry. Screening for cancer of the uterine cervix. IARC Scient Public 1986;(76):91—105.
25. Macgregor J.E., Moss S., Parkin D.M. et al. Cervical cancer screening in North- East Scotland. Screening for cancer of the uterine cervix. IARC Scient Publicat 1986;(76):25—36.
26. Quinn M., Babb P., Jone J. et al. Effect of screening on incidence and mortality from cancer of cervix in England: Evaluation based on routinely collected statistics. BMJ 1999;318:904—8.
27. Mc Croy D.C., Matchar D.B., Bastian L. et al. Evaluation of cervical cytology, evidence report (technology assessment No5) Prepared by Duke University Contract No.290-97-0014 AHCPR Publications No.299-EO101, 1999.
28. Renshaw A.A., Mody D.R., Lozaro R.L. et al. Detection of adeno- carcinoma in situ of the cervix in Papanicolaou tests. Arch Pathol Lab Med 2004;128:153—7.
29. Bray F., Carstensen B., Moller H. et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarc Prev 2005;14:2191—9.
30. Zur Hausen H. Papillomavirus and cancer from basic studies to clinical appli- cation. Nat Rev Cancer 2(5):342—50.
31. Richardson H., Pintos J., Franco E. et al. Determinants of low-risk and high- risk cervical human papillomavirus infec- tions in Montreal University students. Sex Transm Dis 2000;27:79—86.
32. Молчанов Д. Вирус папилломы человека и рак шейки матки: уникальная взаимосвязь и вызов современной медицине. Здор Укр 2007;(1):3.
33. Баджиева Б.А. Генетическая нестабильность и аллельный полиморфизм у больных с дисплазиями и раком шейки матки, вызванными персистенцией ДНК вируса папилломы человека. Автореф. дис. ... канд. мед. наук. М., 2008.
34. Мазуренко Н.Н. Роль вирусов папиллом в канцерогенезе рака шейки матки. Совр онкол 2003;5(1):7—10.
35. Киселев Ф.Л. Вирус-ассоциированные опухоли человека: рак шейки матки и вирусы папиллом. Биохимия 2000;65:79—91.
36. Ponten J., Adami H.O., Bergstrom R. et al. Strategies for global control of cervi- cal cancer. Int J Cancer 1995;60(1):1—26.
37. Минкина О. Цитология против рака. 9 мес 2005;(8).
38. Judson P.L, Habermann E.B., Baxter N.N. et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006;107:1018—22.
39. Sexually transmitted infections quar- terly report. Anogenital warts and HPV infection in England and Wales. CDR week 2001;11(35).
40. Source: Health Protection Agency: http//www.hpa.org.uk/infections/ topics a_z/hiv_and sti/epidemiology/sisludest 05.htm
41. Cox J.T. Epidemiology of cervical intraepithelial neoplasia: the role of human papillomavirus. Baillieres Clin Obstet Gynaecol 1995;9(1):1—37.
42. Olsson S.E., Villa L., Costa R. et al. Induction of immune memory following administration of a prophylactic quadri- valent human papillomavirus (HPV) types 5/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25(26):4931—9.
43. Gardasil. Summary of Product char- acteristics. Human papillomavirus & related genital diseases. Questions & Answers, 2007. p. 57.
44. Garland S.M., Wheeler C.M., Peterz G. et al. Quadrivalent vaccine against Human Papillomavirus to prevent anogenital diseases. N Engl Med 2007;1928—43.
45. Myers E.R., McGrory D.C., Subramanian S. et al. Setting the target for a better cervical screening test: char- acteristics of a cost-effective test for cer- vical neoplasia screening. Obstet Gynecol 2000;96(5 Pt 1):645—52.
46. Nanda K., Mc Grory D.C., Myers E.R. et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormal- ities: a systemic review. Ann Intern Med 2000;132(10):810—9.
47. Kotaniemi-Talonen L., Anttila A., Malila N. et al. Screening with primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008;Jan 7 (Epub ahead of print)
48. Kulasingam S.L., Hughes J.P., Kiviat N.B. et al. Evaluation if human papillomavirus in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288 (14):1749—57.
49. Lörincz A.T. Screening for cervical cancer: new alternatives and research. Salud Pulica Mex 2003;45(Suppl 3):5376—87.
50. Naucler P., Ryd W., Tornberg S. et al. Efficacy of HPV DNA testig with cytol- ogy triage and/or repeat HPVDNA test- ing in primary cervical cancer screening. J Natl Cancer Inst 2009;101(2):88—99.
51. Syrjänen K. New Concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors. Eur J Gynaecol Oncol 2008;29(3): 205—21.
Рецензия
Для цитирования:
Комарова Л.Е. СОВРЕМЕННЫЕ АСПЕКТЫ ЦИТОЛОГИЧЕСКОГО СКРИНИНГА РАКА ШЕЙКИ МАТКИ: ОБЗОР. Опухоли женской репродуктивной системы. 2009;(3-4):78-83. https://doi.org/10.17650/1994-4098-2009-0-3-4-78-83
For citation:
Komarova L.E. CURRENT ASPECTS OF CYTOLOGICAL SCREENING FOR CANCER OF THE CERVIX UTERI: A REVIEW. Tumors of female reproductive system. 2009;(3-4):78-83. (In Russ.) https://doi.org/10.17650/1994-4098-2009-0-3-4-78-83
Просмотров:
704
Послать статью по эл. почте 